Akademik Veri Yönetim Sistemi
VII. International Congress of Molecular Medicine, İstanbul, Türkiye, 5 - 07 Eylül 2019, ss.24-25
Introduction/Aim
Multiple
myeloma (MM) is a B-cell neoplasm characterized by the proliferation of clonal
malignant plasma cells in the bone marrow. The incidence rate is higher in
leukemia and hematologic system comes second after lymphoma among malignant
tumors and constitutes about 15% of all haematological cancers. Despite the
identification of new drugs such as thalidomide, bortezomib, and lenalidomide,
which result in a higher overall response rate and longer life span in MM
treatment, MM is still an untreatable disease.
MicroRNAs
(miRNAs) play a role in critical biological processes such as cell
differentiation, apoptosis and cell proliferation in cancer. Recent studies
have identified miRNA profiles in human myeloma cell lines and primer patient
specimens, and these miRNA expression patterns have been associated with
specific genetic anomalies and the patient's surveillance. The aim of this
thesis work was to examine that difference in expression levels of the 4 miRNAs
(miR-21, miR-32, miR-181a and miR-181b) associated
with response to treatment.
Material
and methods
The
level of expression of (miR-21, miR-32, miR-181a and miR-181b genes) in cells
of Multiple Myeloma patients, RNA samples that obtained from whole blood
samples of 38 MM patients (pre-treatment and post-treatment) and healthy
control groups were investigated the expression pattern of miRNAs using
Real-Time PCR technique.
Results
The
comparison of MM group with healthy controls revealed upregulation of 4 miRNAs
levels before starting of chemotherapy treatment, and after treatment there
were decreased in these levels as response in treatment, but some patients
showed non-response effect to treatment. In chemotherapy response group, the length
of time free from MM disease was associated with decreased miR-32 Expression
levels as a result of treatment response.
Conclusion
miR-21,
miR-32, miR-181a and miR-181b regulate cell differentiation, proliferation,
apoptosis and participate in vascular invasion and metastasis of tumor cells.
We
believe that the inhibition of miR-21, miR-32, miR-181a and miR-181b in future
experiments with anticancer drugs, and the investigation of whether drug
activity develops if these microRNAs are inhibited can also contribute to both
the patient's benefit and the literature.